How does ZEG's PE Ratio compare to its peers?

ZEG is expensive based on its Price-To-Earnings Ratio (30.4x) compared to the peer average (20.6x).

How does ZEG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

ZEG is expensive based on its Price-To-Earnings Ratio (30.4x) compared to the European Pharmaceuticals industry average (21.1x).

What is ZEG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZEG is expensive based on its Price-To-Earnings Ratio (30.4x) compared to the estimated Fair Price-To-Earnings Ratio (28.5x).

What is the Fair Price of ZEG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ZEG (€121.6) is trading below our estimate of [[fair value]] (€287.96)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

AstraZeneca (XTRA:ZEG) - Stock Price, News & Analysis

ZEG Stock Overview

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details

ZEG fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	1/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 57.8% below our estimate of its fair value

Earnings are forecast to grow 18.36% per year

Earnings have grown 29.2% per year over the past 5 years

Analysts in good agreement that stock price will rise by 39.9%

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Unstable dividend track record

AstraZeneca PLC Competitors

Merck KGaA

XTRA:MRK

€60.0b

Dermapharm Holding

XTRA:DMP

€2.0b

Merck

NYSE:MRK

US$244.2b

Novartis

SWX:NOVN

CHF 181.9b

Price History & Performance

Summary of all time highs, changes and price drops for AstraZeneca
Historical stock prices
Current Share Price	UK£121.60
52 Week High	UK£158.20
52 Week Low	UK£112.35
Beta	0.18
11 Month Change	-14.67%
3 Month Change	-21.42%
1 Year Change	2.75%
33 Year Change	19.92%
5 Year Change	39.37%
Change since IPO	121.49%

Recent updates

Shareholder Returns

	ZEG	DE Pharmaceuticals	DE Market
7D	-2.3%	-7.0%	-0.4%
1Y	2.7%	-21.6%	7.1%

Return vs Industry: ZEG exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.

Return vs Market: ZEG underperformed the German Market which returned 7.1% over the past year.

Price Volatility

Is ZEG's price volatile compared to industry and market?
ZEG volatility
ZEG Average Weekly Movement	3.4%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: ZEG has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: ZEG's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1992	89,900	Pascal Soriot	www.astrazeneca.com

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.

AstraZeneca PLC Fundamentals Summary

How do AstraZeneca's earnings and revenue compare to its market cap?
ZEG fundamental statistics
Market cap	€185.71b
Earnings (TTM)	€6.18b
Revenue (TTM)	€48.69b

30.4x

P/E Ratio

3.8x

P/S Ratio

Is ZEG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZEG income statement (TTM)
Revenue	US$51.21b
Cost of Revenue	US$8.91b
Gross Profit	US$42.30b
Other Expenses	US$35.80b
Earnings	US$6.50b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 06, 2025

Earnings per share (EPS)	4.19
Gross Margin	82.61%
Net Profit Margin	12.68%
Debt/Equity Ratio	74.0%

How did ZEG perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

71%

Payout Ratio

ZEG Stock Overview

Rewards

Risk Analysis

AstraZeneca PLC Competitors

XTRA:MRK

€60.0b

XTRA:DMP

€2.0b

NYSE:MRK

US$244.2b

SWX:NOVN

CHF 181.9b

Price History & Performance

Recent News & Updates

CEO & Executive Director recently bought €2.5m worth of stock

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.89 in 3Q 2023)

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Recent updates

CEO & Executive Director recently bought €2.5m worth of stock

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.89 in 3Q 2023)

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

First half dividend of UK£0.78 announced

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Second quarter 2024 earnings released: EPS: US$1.24 (vs US$1.17 in 2Q 2023)

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Shareholder Returns

Price Volatility

About the Company

AstraZeneca PLC Fundamentals Summary

30.4x

3.8x

Earnings & Revenue

Dividends

2.3%

71%